Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AHCY
REST API REST API
Homo sapiens
AHCY is differentially expressed in 292 experiments: 122 organism parts: liver, kidney, ... (120 more);, 202 disease states: normal, colon carcinoma, ... (200 more);, 114 cell types 325 cell lines 41 compound treatments and 73 other conditions.
Synonyms SAHH
Orthologs D3ZQH8_RAT (Rattus norvegicus)   Ahcy (Rattus norvegicus)   ahcy (Danio rerio)   F1P3F1_CHICK (Gallus gallus)   Ahcy (Mus musculus)   SAHH_BOVIN (Bos taurus)   SAH1 (Saccharomyces cerevisiae)   D4AB27_RAT (Rattus norvegicus)   Ahcy13 (Drosophila melanogaster)   Gm4737 (Mus musculus)   ahcy (Xenopus laevis)   AHCY (Canis familiaris)   (Compare orthologs)
Gene Ontology Term one-carbon metabolic process, cytosol, cofactor binding, cytoplasm, oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor, adenosylhomocysteinase activity, methylation, cellular amino acid biosynthetic process, hydrolase activity, xenobiotic metabolic process, melanosome, oxidation-reduction process, ketol-acid reductoisomerase activity
InterPro Term D-isomer_2_OHA_DH_NAD-bd, Ado_hCys_hydrolase_NAD-bd, Adenosylhomocysteinase, IlvN
UniProt Accession Q1RMG2, P23526, F5H737
Gene-Disease Assocation HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY
Search EB-eye ENSG00000101444
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
Raji
2
E-GEOD-96, E-MTAB-37
HT1080
2
E-MTAB-37, E-GEOD-20089
HepG2
2
E-GEOD-21154, E-MTAB-37
MDA-MB-231
2
E-TABM-420, E-MTAB-62
319 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (56 experiments)

Factor Value U/D Experiments
macrophage
1
3
E-GEOD-8286, E-GEOD-360, E-GEOD-5099, E-GEOD-3982
CD4+ T cell
1
3
E-GEOD-16190, E-AFMX-5, E-MTAB-24, E-MTAB-25
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
stromal cell
2
E-MEXP-2034, E-GEOD-10797
undifferentiated cell
1
E-GEOD-21668
CD34+ hematopoietic progenitor cell
1
E-GEOD-19240
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-1121, E-GEOD-2549, ... (48 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-GEOD-3726, E-MTAB-62, E-MTAB-37, E-MTAB-57
lung adenocarcinoma
3
E-GEOD-2514, E-MEXP-231, E-MTAB-62
prostate carcinoma
1
3
E-GEOD-96, E-MTAB-62, E-MEXP-1327, E-MTAB-37
acute promyelocytic leukemia
2
E-GEOD-995, E-GEOD-96
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
196 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-697, E-GEOD-5824, E-MEXP-1958, E-MEXP-2590, ... (29 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-4006, E-GEOD-995, E-GEOD-3284, E-GEOD-5339
interferon-gamma + lipopolysaccharide
2
E-GEOD-5099, E-GEOD-7307
NaOH
1
E-MEXP-2590
HMB-PP (phosphoantigen)
1
E-MEXP-1601
PGE2
1
E-MEXP-1230
4OH-tamoxifen
1
E-GEOD-2292
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-22148, E-TABM-147

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-TABM-321, E-GEOD-18736, E-TABM-868, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-20540, E-MEXP-1446, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-MEXP-973, E-GEOD-21909, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.371 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM